Background: Septic shock, a critical condition characterized by organ failure, presents a substantial mortality risk in intensive care units (ICUs), with the 28-day mortality rate possibly reaching 40%. Conventional management of septic shock typically involves the administration of antibiotics, supportive care for organ dysfunction, and, if necessary, surgical intervention to address the source of infection. In recent decades, extracorporeal blood purification therapies (EBPT) have emerged as potential interventions aimed at modulating the inflammatory response and restoring homeostasis in patients with sepsis. Likewise, sequential extracorporeal therapy in sepsis (SETS) interventions offer comprehensive organ support in the setting of multiple organ dysfunction syndrome (MODS). The EROICASS study will assess and describe the utilization of EBPT in patients with septic shock. Additionally, we will evaluate the potential association between EBPT treatment utilization and 90-day mortality in septic shock cases in Italy. Methods: The EROICASS study is a national, non-interventional, multicenter observational prospective cohort study. All consecutive patients with septic shock at participating centers will be prospectively enrolled, with data collection extending from intensive care unit (ICU) admission to hospital discharge. Variables including patient demographics, clinical parameters, EBPT/SETS utilization, and outcomes will be recorded using a web-based data capture system. Statistical analyses will encompass descriptive statistics, hypothesis testing, multivariable regression models, and survival analysis to elucidate the associations between EBPT/SETS utilization and patient outcomes. Conclusions: The EROICASS study provides valuable insights into the utilization and outcomes of EBPT and SETS in septic shock management. Through analysis of usage patterns and clinical data, this study aims to guide treatment decisions and enhance patient care. The implications of these findings may impact clinical guidelines, potentially improving survival rates and patient outcomes in septic shock cases.

The use of extracorporeal blood purification therapies and sequential extracorporeal support in patients with septic shock (EROICASS): a study protocol for a national, non-interventional, observational multicenter, prospective study / De Rosa, Silvia; Ferrari, Fiorenza; Greco, Massimiliano; Pota, Vincenzo; Umbrello, Michele; Cotoia, Antonella; Pasin, Laura; Nalesso, Federico; Paternoster, Gianluca; Villa, Gianluca; Lassola, Sergio; Miori, Sara; Sanna, Andrea; Cantaluppi, Vincenzo; Marengo, Marita; Valente, Fabrizio; Fiorentino, Marco; Brunori, Giuliano; Bellani, Giacomo; Giarratano, Antonino. - In: JOURNAL OF ANESTHESIA, ANALGESIA AND CRITICAL CARE. - ISSN 2731-3786. - 4:1(2024), pp. 161-166. [10.1186/s44158-024-00153-7]

The use of extracorporeal blood purification therapies and sequential extracorporeal support in patients with septic shock (EROICASS): a study protocol for a national, non-interventional, observational multicenter, prospective study

De Rosa, Silvia
;
Brunori, Giuliano;Bellani, Giacomo;
2024-01-01

Abstract

Background: Septic shock, a critical condition characterized by organ failure, presents a substantial mortality risk in intensive care units (ICUs), with the 28-day mortality rate possibly reaching 40%. Conventional management of septic shock typically involves the administration of antibiotics, supportive care for organ dysfunction, and, if necessary, surgical intervention to address the source of infection. In recent decades, extracorporeal blood purification therapies (EBPT) have emerged as potential interventions aimed at modulating the inflammatory response and restoring homeostasis in patients with sepsis. Likewise, sequential extracorporeal therapy in sepsis (SETS) interventions offer comprehensive organ support in the setting of multiple organ dysfunction syndrome (MODS). The EROICASS study will assess and describe the utilization of EBPT in patients with septic shock. Additionally, we will evaluate the potential association between EBPT treatment utilization and 90-day mortality in septic shock cases in Italy. Methods: The EROICASS study is a national, non-interventional, multicenter observational prospective cohort study. All consecutive patients with septic shock at participating centers will be prospectively enrolled, with data collection extending from intensive care unit (ICU) admission to hospital discharge. Variables including patient demographics, clinical parameters, EBPT/SETS utilization, and outcomes will be recorded using a web-based data capture system. Statistical analyses will encompass descriptive statistics, hypothesis testing, multivariable regression models, and survival analysis to elucidate the associations between EBPT/SETS utilization and patient outcomes. Conclusions: The EROICASS study provides valuable insights into the utilization and outcomes of EBPT and SETS in septic shock management. Through analysis of usage patterns and clinical data, this study aims to guide treatment decisions and enhance patient care. The implications of these findings may impact clinical guidelines, potentially improving survival rates and patient outcomes in septic shock cases.
2024
1
De Rosa, Silvia; Ferrari, Fiorenza; Greco, Massimiliano; Pota, Vincenzo; Umbrello, Michele; Cotoia, Antonella; Pasin, Laura; Nalesso, Federico; Patern...espandi
The use of extracorporeal blood purification therapies and sequential extracorporeal support in patients with septic shock (EROICASS): a study protocol for a national, non-interventional, observational multicenter, prospective study / De Rosa, Silvia; Ferrari, Fiorenza; Greco, Massimiliano; Pota, Vincenzo; Umbrello, Michele; Cotoia, Antonella; Pasin, Laura; Nalesso, Federico; Paternoster, Gianluca; Villa, Gianluca; Lassola, Sergio; Miori, Sara; Sanna, Andrea; Cantaluppi, Vincenzo; Marengo, Marita; Valente, Fabrizio; Fiorentino, Marco; Brunori, Giuliano; Bellani, Giacomo; Giarratano, Antonino. - In: JOURNAL OF ANESTHESIA, ANALGESIA AND CRITICAL CARE. - ISSN 2731-3786. - 4:1(2024), pp. 161-166. [10.1186/s44158-024-00153-7]
File in questo prodotto:
File Dimensione Formato  
derosa_brunori_bellani_2024_jaacc.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/428450
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact